Riken Vitamin Co., Ltd. AI Stock Analysis
Want to see JP:4526 full AI Analyst Report?
Riken Vitamin Co., Ltd. (4526) AI Stock Analysis
Riken Vitamin Co., Ltd.
(TSE/TYO:4526)
Overall score reflects a strong, low-leverage balance sheet and constructive price momentum, supported by reasonable valuation and a solid dividend yield. The key risk tempering the score is the recent deterioration in cash flow conversion and softer margins versus the 2024–2025 peak, which raises questions about near-term earnings and cash durability.
Riken Vitamin Co., Ltd. (4526) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 104.66B
- Dividend Yield
- 3.09%
- Average Volume (3M)
- 94.97K
- Price to Earnings (P/E)
- 14.9
- Beta (1Y)
- 0.26
- Revenue Growth
- 3.11%
- EPS Growth
- -17.81%
- Country
- Japan
- Employees
- 1,887
- Sector
- Consumer Defensive
- Sector Strength
- 62
- Industry
- Packaged Foods
Riken Vitamin Co., Ltd. Business Overview & Revenue Model
Company Description
Riken Vitamin Co., Ltd., based in Tokyo, Japan, operates across several key sectors: food ingredients, food applications, healthcare, and chemicals. The company provides a diverse portfolio of food additives, including emulsifiers used in a wide arra...
Riken Vitamin Co., Ltd. Financial Statement Overview
Summary
Financials are solid overall: steady revenue growth and acceptable profitability (2026 gross margin ~31%, net margin ~7%), supported by a very conservative balance sheet (debt-to-equity ~0.09). The main drag is weaker cash conversion and a sharp decline in free cash flow in 2026 (~¥0.9B vs ~¥3.1B in 2025 and ~¥7.4B in 2024), alongside margin normalization versus 2024–2025.
Income Statement
74PositiveBalance Sheet
86Very PositiveCash Flow
58Neutral| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 98.18B | 96.30B | 95.58B | 91.48B | 88.75B | 79.23B |
| Gross Profit | 30.14B | 29.77B | 31.27B | 29.89B | 27.24B | 25.57B |
| EBITDA | 11.90B | 11.58B | 16.04B | 15.35B | 11.71B | 24.23B |
| Net Income | 7.08B | 7.04B | 9.39B | 8.76B | 6.41B | 21.58B |
Balance Sheet | ||||||
| Total Assets | 117.34B | 116.39B | 113.00B | 118.78B | 105.22B | 102.66B |
| Cash, Cash Equivalents and Short-Term Investments | 17.91B | 20.07B | 22.30B | 23.38B | 19.16B | 17.30B |
| Total Debt | 7.40B | 7.14B | 9.98B | 16.09B | 14.60B | 17.57B |
| Total Liabilities | 32.94B | 33.01B | 33.80B | 42.13B | 33.85B | 36.12B |
| Stockholders Equity | 84.36B | 83.34B | 79.16B | 76.61B | 71.34B | 66.52B |
Cash Flow | ||||||
| Free Cash Flow | 0 | 925.00M | 3.12B | 7.42B | 5.67B | 3.44B |
| Operating Cash Flow | 0 | 5.96B | 7.89B | 10.45B | 7.83B | 6.82B |
| Investing Cash Flow | 0 | 1.75B | 353.00M | -554.00M | -2.03B | -3.66B |
| Financing Cash Flow | 0 | -8.04B | -9.96B | -7.08B | -4.58B | -7.57B |
Riken Vitamin Co., Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4526, the sentiment is Positive. The current price of 3565.00 is above the 20-day moving average (MA) of 3378.75, above the 50-day MA of 3286.10, and above the 200-day MA of 3029.20, indicating a bullish trend. The MACD of 115.09 indicates Negative momentum. The RSI at 60.71 is Neutral, neither overbought nor oversold. The STOCH value of 81.24 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4526.
Riken Vitamin Co., Ltd. Peers Comparison
Overall Rating
- JP:452677Outperform
JP:226477Outperform
JP:313966Neutral
JP:280262Neutral
JP:260760Neutral
JP:292751Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| JP:4526 | 77Outperform | JPY 83.92B | 14.91 | ― | 3.09% | 3.11% | -17.81% |
| JP:2264 | 77Outperform | JPY 389.75B | 18.28 | ― | 2.09% | 2.67% | 112.23% |
| JP:3139 | 66Neutral | JPY 34.64B | 9.85 | ― | 4.27% | 5.61% | -15.32% |
| Sector * | 62Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% |
| JP:2802 | 62Neutral | JPY 4.07T | 26.44 | 20.53% | 1.15% | 9.89% | 126.77% |
| JP:2607 | 60Neutral | JPY 399.38B | 23.90 | ― | 1.35% | 3.57% | 54.54% |
| JP:2927 | 51Neutral | JPY 11.99B | 10.17 | ― | 4.76% | 5.11% | -19.41% |
* Consumer Defensive Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:4526 | Riken Vitamin Co., Ltd. | 3565.00 | 810.11 | 29.41% | |
| JP:2802 | Ajinomoto Co | 4264.00 | 519.84 | 13.88% | |
| JP:2264 | Morinaga Milk Industry Co., Ltd. | 1232.50 | 340.36 | 38.15% | |
| JP:2607 | Fuji Oil Holdings, Inc. | 4207.00 | 912.00 | 27.68% | |
| JP:2927 | AFC-HD AMS Life Science Co., Ltd. | 841.00 | 13.98 | 1.69% | |
| JP:3139 | Lacto Japan Co., Ltd. | 3470.00 | -39.12 | -1.11% |
Riken Vitamin Co., Ltd. Corporate Events
Riken Vitamin Announces Progressive Dividend Policy, Higher Forecast
Riken Vitamin Co., Ltd. announced that its board had resolved to change the company’s dividend policy and increase its dividend forecast. The new policy, applying from the fiscal year ending March 31, 2027, calls for progressive dividends and a minim...
Riken Vitamin Revises Medium-Term Management Plan 2027
Riken Vitamin’s board resolved to revise its Medium-Term Management Plan 2027 after overseas operations recorded an operating loss in fiscal 2025 amid a Chinese economic downturn and intensified commodity-price competition in Southeast Asia and Europ...
Riken Vitamin Reports Higher Six-Month Sales and Lower Operating Profit
Riken Vitamin Co., Ltd. is listed on the Tokyo Stock Exchange under stock code 4526; the release covers its consolidated results for the six months ended September 30, 2026. The company reported net sales of 50,189 million yen, up 6.2% year over year...
Riken Vitamin Maintains Stable Payout With 55 Yen Interim Dividend
Riken Vitamin Co., Ltd. has resolved to pay an interim dividend of 55 yen per share for the fiscal year ending March 2027, with a record date of September 30, 2026 and payment scheduled for December 7, 2026. The interim payout, sourced from retained...
Riken Vitamin Nears Share Buyback Ceiling with Tokyo Market Purchases
Riken Vitamin Co., Ltd. has completed a share buyback program under a Board-approved mandate, acquiring 111,700 of its own common shares via market purchases on the Tokyo Stock Exchange between September 1 and September 18, 2026. The latest tranche c...
Riken Vitamin Advances Share Buyback, Acquires Over Half of Authorized Amount
Riken Vitamin Co., Ltd. has disclosed the latest progress in its share buyback program, reporting the purchase of 164,300 common shares for approximately 536 million yen on the Tokyo Stock Exchange between August 1 and August 31, 2026. This move is p...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 17, 2026